Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
02552 HUA MEDICINE-B
RTNominal unchange1.590 0.000 (0.000%)
Others

16/08/2019 14:25

{I-bank focus}Goldman cuts Hua Medicine (02552) to HK$11.6

[ET Net News Agency, 16 August 2019] Goldman Sachs lowered its target price for Hua
Medicine (02552) to HK$11.6 from HK$12.9 and maintained its "buy" rating.
The research house said Hua's 1H net loss was Rmb236mn. Its cash of Rmb1,246mn by 1H
could cover company's operations in 2019/20, with Goldman's estimated R&D spending of
Rmb347mn/Rmb426mn.
Goldman sees 4Q 2019/2Q 2020 as critical for Hua, with 24-week efficacy data on
Dorzagliatin as monotherapy (estimated in 4Q 2019) and in combination with metformin
(estimated in 2Q 2020) could potentially be released, which may lead to global
collaborations and NDA filing. (KL)

Back to Others

Remark: Real time quote last updated: 23/04/2024 17:59
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.